文献速递炎症性肠病

南锡与米兰队列中炎症性肠病患者的COVID-19发病情况及特征

Incidence and Patterns of COVID-19 Among Inflammatory Bowel Disease Patients From the Nancy and Milan Cohorts.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-04-30

本文介绍COVID-19疫情在意大利伦巴第和法国东北部严重流行,IBD患者与医生担忧免疫抑制剂或生物制剂可能增加感染风险,IOIBD已建立国际注册登记SECURE-IBD以追踪IBD合并COVID-19病例及其结局与IBD相关药物之间的关联。

要点

  • IBD患者使用免疫抑制剂或生物制剂是否增加COVID-19风险是当前关注焦点
  • IOIBD建立国际注册SECURE-IBD追踪IBD合并COVID-19病例
  • 该注册将描述感染患者结局及IBD相关药物与结局的关联

核心结论

  • IBD患者与医生担忧免疫抑制剂或生物制剂可能增加COVID-19感染风险
  • SECURE-IBD国际注册将描述感染患者结局及IBD相关药物与结局的关联

研究设计与样本

  • 基于南锡与米兰队列的描述性报告
  • 提及IOIBD建立的国际注册SECURE-IBD用于追踪IBD合并COVID-19病例

主要发现

  • 意大利(尤其伦巴第)和法国(尤其东北部)受疫情严重影响

临床怎么用

  • 关注IBD合并COVID-19患者的登记与随访
  • 通过SECURE-IBD注册收集感染病例结局与用药关联信息

局限性

  • 摘要未报告具体样本量、发病率或统计结果

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The first cases of COVID-19 infection were reported in December, 2019, in Wuhan, China. Italy (in particular Lombardy) and France (in particular Northeast) have been gravely hit. Both physicians and inflammatory bowel disease (IBD) patients are deeply concerned that immunosuppressants or biologics may increase the risk of COVID-19 infection. IOIBD has put in place an international registry, SECURE-IBD, for tracking all the cases with IBDs infected by COVID-19 (SECURE-IBD registry: http://www.covidibd.org). It will describe the outcomes of infected patients and the association between IBD-related medications and these outcomes.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Allocca M, Fiorino G, Zallot C, et al. Incidence and Patterns of COVID-19 Among Inflammatory Bowel Disease Patients From the Nancy and Milan Cohorts. Clin Gastroenterol Hepatol. 2020. PMID: 32360811. doi:10.1016/j.cgh.2020.04.071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。